Eris Lifesciences Limited

NSE ERIS.NS

Eris Lifesciences Limited Operating Income Margin for the year ending March 31, 2024: 26.02%

Eris Lifesciences Limited Operating Income Margin is 26.02% for the year ending March 31, 2024, a 2.55% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Eris Lifesciences Limited Operating Income Margin for the year ending March 31, 2023 was 25.37%, a -20.73% change year over year.
Eris Lifesciences Limited Operating Income Margin for the year ending March 31, 2022 was 32.01%, a -1.51% change year over year.
Eris Lifesciences Limited Operating Income Margin for the year ending March 31, 2021 was 32.50%, a 6.85% change year over year.
Eris Lifesciences Limited Operating Income Margin for the year ending March 31, 2020 was 30.42%, a -4.76% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: ERIS.NS

Eris Lifesciences Limited

CEO	Mr. Amit Indubhushan Bakshi
IPO Date	June 30, 2017
Location	India
Headquarters	Shivarth Ambit
Employees	3,620
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Key trends

Past 5 years